tiprankstipranks

Intellia’s Lonvo-z: Promising Phase 1 Results Amid Market Competitiveness and Safety Concerns

Intellia’s Lonvo-z: Promising Phase 1 Results Amid Market Competitiveness and Safety Concerns

Citi analyst David Lebowitz maintained a Hold rating on Intellia Therapeutics (NTLAResearch Report) yesterday and set a price target of $10.00.

Don’t Miss TipRanks’ Half-Year Sale

David Lebowitz has given his Hold rating due to a combination of factors. The recent Phase 1 data for Intellia’s lonvo-z in treating hereditary angioedema (HAE) showed promising results, with a significant reduction in monthly attack rates among patients. However, the Phase 2 data presented earlier indicated a less competitive reduction rate compared to existing therapies, raising concerns about its competitiveness in the market.
Additionally, while the Phase 1 results suggest the potential for lonvo-z to be a ‘functional cure’ if similar outcomes are achieved in the Phase 3 study, there are ongoing safety concerns with Intellia’s gene therapy platform. These concerns, coupled with the high expectations for the upcoming Phase 3 results, contribute to the Hold rating as investors await further data to assess the therapy’s long-term viability and market position.

According to TipRanks, Lebowitz is a 3-star analyst with an average return of 2.6% and a 53.14% success rate. Lebowitz covers the Healthcare sector, focusing on stocks such as Exelixis, Incyte, and Intellia Therapeutics.

Disclaimer & DisclosureReport an Issue

1